Table 2.
Summary of immunofluorescence stained cells in individual patients.
| p= * | ||||||
|---|---|---|---|---|---|---|
| Patient ID | 1 | 3 | 5 | 2 | 4 | |
| Gleason Grade Group | 2 | 3 | 3 | 4 | 5 | |
| PSMA-PET status | + | - | + | - | + | |
| Total no. CTC | 31 | 19 | 18 | 27 | 29 | |
| PSMA, n (%) | 0 (0.0) | 0 (0.0) | 5 (27.8) | 0 (0.0) | 0 (0.0) | 0.96 |
| PD-L1, n (%) | 20 (64.5) | 3 (15.8) | 3 (16.7) | 0 (0.0) | 0 (0.0) | <0.001 |
| PAP, n (%) | 0 (0.0) | 6 (31.6) | 4 (22.2) | 3 (11.1) | 2 (6.9) | 0.92 |
| PSMA/PD-L1, n (%) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | - |
| PSMA/PAP, n (%) | 6 (19.4) | 3 (15.8) | 6 (33.3) | 0 (0.0) | 0 (0.0) | 0.005 |
| PD-L1/PAP, n (%) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | - |
| PSMA/PD-L1/PAP, n (%) | 5 (16.1) | 7 (36.8) | 0 (0.0) | 24 (88.9) | 27 (93.1) | 0.005 |
| Clusters (no.) | 4 (12.3) | 3 (15.8) | 4 (22.2) | 1 (3.7) | 0 (0.0) | <0.0001 |
| Nuclei+ cells (no. PSMA/PD-L1/PAP) † |
4 | 5 | 8 | 11 | 0 | - |
* Chi-square test for trend; † not counted as positive CTC.